MERCK and Pfizer have announced that the Therapeutic Goods Administration (TGA) has approved registration of Bavencio (avelumab), the first immunotherapy to treat metastatic Merkel cell carcinoma (mMCC), a rare but highly aggressive skin cancer associated with excessive sun exposure.
From a pharmacist point of view, the condition presents as 'fleshy' painless nodules and like melanoma, can metastasise to other organs.
Diagnosis of the condition can sometimes be a lengthy process and Australia has the highest rates in the world.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Jan 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Jan 18
